Pfizer To Supply 6 Mln Paxlovid Treatment Courses To Fight Covid-19

Pfizer Inc. (PFE) said on Thursday that it will supply up to six million treatment courses of its Covid-19 oral treatment, Paxlovid, which includes Nirmatrelvir and Ritonavir tablets, to Global Fund as part of its Covid-19 Response Mechanism or C19RM.

The C19RM is focused on providing grant support to low- and middle-income countries to provide Covid-19 tests, treatments, personal protective equipment, and others.

Paxlovid treatment courses will be available for procurement by the 132 Global Fund-eligible low-and-middle-income countries starting in 2022.

The Global Fund is an agreement with UNICEF for the supply of up to four million treatment courses for low- and middle-income countries earlier this year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Stocks staged a significant recovery attempt after pulling back sharply in early trading on Wednesday but still ended the day modestly lower. The major averages gave back ground after moving sharply higher over the two previous sessions. Three scientists have shared the Nobel Prize for Chemistry for their work that led to the development of linking molecules together, known as click chemistry, and bioorthogonal chemistry. Morten Meldal and K. Barry Sharpless have laid the foundation for a functional form of chemistry - click chemistry - in which molecular building blocks snap together quickly and efficiently. Carolyn R. Bertozzi The Institute for Supply Management released a report on Wednesday showing a modest slowdown in the pace of growth in U.S. service sector activity in the month of September. The ISM said its services PMI edged down to 56.7 in September from 56.9 in August, although a reading above 50 still indicates growth in the sector.
Follow RTT